March 2017 in “Journal of endourology” The journal retracted an article due to inaccurate statistics and asked the authors to revise and resubmit it.
January 2017 in “Corpus Université Laval (Université Laval)” Dutasteride may protect brain cells in early Parkinson's, while progesterone helps neuron recovery.
December 2016 in “The Journal of urology/The journal of urology” Castration significantly reduces prostate size and BPH symptoms.
December 2016 in “University of Birmingham Institutional Research Archive (University of Birmingham)” Glucocorticoids reduce fat production in liver cells, while androgens increase it in females; manipulating certain enzymes can influence these effects.
August 2016 in “Journal of Investigative Dermatology” Dutasteride improved hair density and thickness in men not helped by finasteride, with minimal side effects.
August 2016 in “Journal of Investigative Dermatology” Some men don't respond to common hair loss treatments, but a new inhibitor, FOL-005, shows promise for targeting unwanted hair growth.
March 2016 in “National Repository of Dissertations in Serbia” Dutasteride is more cost-effective than finasteride for treating benign prostatic hyperplasia in Montenegro.
March 2016 in “Korean Journal of Medicine” Doxazosin can cause male breast growth and milk production.
January 2016 in “Archivio italiano di urologia, andrologia” The document concludes that the risk of sexual side effects from 5-alpha-reductase inhibitors is low and often temporary, but more research is needed on potential permanent effects.
January 2016 in “The Korean Journal of Internal Medicine” Doxazosin may cause breast enlargement and pain in men.
January 2016 in “Indian dermatology online journal” The patient has frontal fibrosing alopecia (FFA).
October 2015 in “Prostate Cancer” Finasteride and dutasteride reduce prostate cancer risk, but finasteride may increase higher-grade cancer risk.
September 2015 in “한국임상약학회지” The document's conclusion cannot be determined without content.
The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.
November 2014 in “British Journal of Dermatology” Male hair loss is mainly due to thinner hair, not less hair.
September 2014 in “PubMed Central” BPH treatments can cause sexual side effects affecting quality of life.
July 2014 in “Urologia Journal” 5ARI treatment improves PSA test accuracy for prostate cancer diagnosis.
January 2014 in “Anales Médicos de la Asociación Médica del Centro Médico ABC” The treatment effectively promoted hair growth with minimal side effects.
The models can help find better inhibitors for conditions like baldness and prostate disorders.
December 2013 in “Estudo Geral (Universidade de Coimbra)” Modified steroidal inhibitors showed promise in treating hormone-dependent cancers.
July 2013 in “Edinburgh Research Archive (University of Edinburgh)” Dutasteride may reduce insulin sensitivity and increase body fat.
February 2013 in “Journal of The American Academy of Dermatology” Using hair loss drugs finasteride and dutasteride may cause sexual side effects.
December 2012 in “Canadian Urological Association Journal” 5-alpha reductase inhibitors help treat prostate issues in aging men, but their role in cancer prevention is debated.
December 2012 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” There are several promising treatments for hair loss, including dutasteride, latanoprost, ketoconazole shampoo, anti-androgens, laser/light treatment, and platelet-rich plasma, but more research is needed.
July 2012 in “The Journal of Urology” Testosterone increases muscle mass regardless of DHT conversion blocking.
August 2011 in “Der Urologe” 5α-reductase inhibitors lower overall prostate cancer risk but not high-grade cancer risk; longer-term screening and new treatments show promise.
Dutasteride reduces prostate cancer risk by 23% in high-risk men.
Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.
October 2006 in “Urology” The study found that different criteria led to different patient groups in the CombAT study compared to the MTOPS study.
September 2006 in “Aktuelle Urologie” Combination drug therapies are more effective for high-risk BPS patients but have more side effects and costs.